Portfolio News
Sofinnova Industrial Biotech
Afyren provides business update on its Afyren Neoxy plant
- Successful completion of several long production cycles to deliver the first commercial volumes of acids
- Confirmation of the objective to start continuous production in 2024
Clermont-Ferrand/Lyon, June 4, 2024, 7:30 am CEST – AFYREN, a greentech company that offers manufacturers bio-based, low-carbon ingredients produced using unique fermentation technology based on a completely circular model, provided an update on recent activity of its AFYREN NEOXY plant during a visit organised for individual and institutional shareholders, and confirmed its target to start continuous production in 2024.
“After several months of tests and trials, our teams have now a good control of our process and its critical steps. I welcome their resilience and determination to meet the challenges related to the unique and innovative nature of our process. Based on these achievements, we are very confident in our ability to ensure the start of continuous production of AFYREN NEOXY in 2024, and to make AFYREN a leading player in industrial green chemistry worldwide”, states Nicolas Sordet, Chief Executive Officer of AFYREN.
The work undertaken since the beginning of the year, particularly on the separation stage, paid off. The improved reliability of the equipment combined with the increased skills of the teams regarding a critical stage of the process enabled several long production cycles, carried out under operating conditions in line with expectations.
The successes of the last few weeks enabled several tons of acid to be produced. These acids are currently in the purification phase, the final stage of the process. AFYREN does not foresee any technical difficulties at this stage, although a running-in period is required. The current operations should enable the first commercial volumes of bio-based acids to be delivered to AFYREN’s partners.
Improvements identified in recent months following progress made in the conduct of operations will be implemented in the coming weeks. This work will be carried out without impacting the start-up schedule: AFYREN confirms its objective to start continuous production in 2024 and reach break-even in 2025.
AFYREN NEOXY’s shareholders will cover additional financing requirements, in particular operating costs related to the final weeks of start-up.
Related News
Asahi Kasei completes the recommended public cash offer and becomes the owner of 93.30 per cent of all shares in Calliditas
AFYREN announces signing of new commercial contract with US nutraceutical maker
HighLife receives ISO 13485 certification of its quality management system
Mediar Therapeutics initiates second clinical program in portfolio of novel first-in-class antibodies designed to halt fibrosis
Video: Sofinnova Partners 2024 annual general meeting